Tharimmune (THAR) Competitors

Aprea Therapeutics (NASDAQ:APRE) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations.

Which has more risk and volatility, APRE or THAR?

Aprea Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in APRE or THAR?

34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 12.8% of Aprea Therapeutics shares are owned by insiders. Comparatively, 2.4% of Tharimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media favor APRE or THAR?

In the previous week, Tharimmune had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 2 mentions for Tharimmune and 0 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.00 beat Tharimmune's score of -0.03 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aprea Therapeutics	Neutral
Tharimmune	Neutral

Do analysts recommend APRE or THAR?

Aprea Therapeutics presently has a consensus target price of $15.50, indicating a potential upside of 933.06%. Tharimmune has a consensus target price of $17.00, indicating a potential upside of 1,451.09%. Given Tharimmune's stronger consensus rating and higher probable upside, analysts plainly believe Tharimmune is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tharimmune	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Is APRE or THAR more profitable?

Tharimmune has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,029.50%. Aprea Therapeutics' return on equity of -57.86% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-1,029.50%	-57.86%	-47.94%
Tharimmune	N/A	-167.63%	-130.18%

Which has higher earnings & valuation, APRE or THAR?

Tharimmune has lower revenue, but higher earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$580K	14.21	-$14.29M	-$2.38	-0.63
Tharimmune	N/A	N/A	-$9.32M	-$9.74	-0.11

Does the MarketBeat Community believe in APRE or THAR?

Aprea Therapeutics received 54 more outperform votes than Tharimmune when rated by MarketBeat users. However, 100.00% of users gave Tharimmune an outperform vote while only 57.14% of users gave Aprea Therapeutics an outperform vote.

Company	Underperform	Outperform
Aprea Therapeutics	Outperform Votes 56 57.14%	Underperform Votes 42 42.86%
Tharimmune	Outperform Votes 2 100.00%	Underperform Votes No Votes

Summary

Aprea Therapeutics and Tharimmune tied by winning 9 of the 18 factors compared between the two stocks.